Garro OM

Language: Spanish
References: 13
Page: 375-379
PDF size: 173.47 Kb.

ABSTRACT

Fortunately statin therapy is well tolerated, but clinicians should be aware of the risk for myopathy, rhabdomyolysis, and, rarely, peripheral neuropathy as complications. As more people use statin therapy, the incidence of these adverse affects will likely increase. Clinicians may be able to detect the neuromuscular complications early and prevent more severe complications. Further research is necessary to better understand the etiology and management of statinrelated neuromuscular disease.

REFERENCES

1. Ahn Do Sung C ,Neuromuscular Complications of Statins, physical medicine and rehabilitation clinics of north America 19(2008)47-57

2. Botempo Laura J, ,Rhabdomyoly sis,Rosen’sEmergency Medicine: Concepts and ClinicalPractice, 6th ed., 2006 Mosby.

3. Camp Nancy E , RN, MS, Washington, DCSection Editor: Allison A. Muller, PharmD, Drugand toxin induced rhabdomyolysis, journal of emergency nursing September 2009

4. Chatzizisis Yianis , Misisrli Getsthimani, Hatzitolios Apostolos I, Giannoglou Geroge D, European Journal of Internal Medicine 19(2008) 568-574

5. Jamal Shelina BSc, Eisenber Mark J. MD,MPH,and Chistopoulos Stavroula,MD, Rhabdomyolysisas sociatedwithhydroxymethylglutar yl-coenzyme A reductasa inhibitors, American HeartJournalVolume 147,number 6 ,2004

6. Kushalaf Hani A,MB, BChEmerging ToxicNeuropathies and Myopathies,Emerging Toxic Neuropathies and Myopathies 29 (2011)679-687.

7. Mor Adam,MDa, Wortmann Robert L. MD , Hal J Mitnick Macr,MDc, Pillinger Michael H., MDd ,Drugs Causing Muscle Disease, rheumatic dis clin N m 37 (2011) 219-231.

8. Revista de Medicina Interna y Medicina Crítica Volumen 1, Número 5 , Septiembre 2004

9. Ridker Paul,MD, Danielson Eleanor ,MIA, Fonseca Francisco A, MD, Genest Jacques,MD,Gotto Antonio M,Jr, MD, Kastelein John J.P. ,MD, Libby Peter, MD, Lorenzatti Alberto,MD, MacFadyen Jean,B.A, Nordestgaard Borge G,MD, Shepeherd James,MD, Willerson James,MD,and Glyun Robert J Sc.D., forthe JUPITER StudyGroup, RosuvastatintoPrevent Vascular Events in Men and WomenwithElevated C-Reactive Protein, new England journal of medicine november 20, 2008 vol. 359 no. 21

10. Smith Edwuard C, MD , El Gharbawy Areeg,MD, Koeberl Dwight, MD, PhDb,Metabolic Myopathies: Clinical Features and Diagnostic Approach ,rheumatic dis clin N m 37 (2011) 201-217

11. Unal Aydin, Torun Edip, Hayrisipahioglu Murat, Tokgoz Blent, Gungor Kaya Mehmet, OktayOymak ,Fenofibrate- Induced Acute Renal Failure Due to Massive Rhabdomyolusis After Coadministration of statin, Internal Medicine 47:1017-1019,2008

12. Vanholer Raymond , Sukrusever Mehemer , Erek Ekrem and Lameire Norbert ,Rhabdomyolysis ,J Am SocNephrol 11: 1553–1561, 2000

13. Yan Song Wu, LI Heng, Chen Jianghua, Rhabdomyolysis associated with fibrate therapyEur J ClinPharmacol (2009) 65:1169-1174